X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Amri Announces Strategic Alliance To Advance Mass Spectrometry Capabilities For Drug Discovery

Yuvraj_pawp by Yuvraj_pawp
8th February 2017
in Americas, Projects

AMRI , a global contract research and manufacturing organization working to improve patient outcomes and quality of life, has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high throughput mass spectrometry (MS) for drug discovery.

AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and HighRes Biosolutions. The system will be deployed at AMRI’s Integrated Drug Discovery Center and, in accordance with the terms of the alliance, Bruker Daltonics and HighRes Biosolutions will provide training and consulting to AMRI biologists to aid them in their development of protocols on the system that can be used for high throughput screening drug discovery programs.

“We see incredible potential for this technology at AMRI’s Integrated Drug Discovery Center as this is the first technology to allow MS-based screening and analysis at the output required for cost-effective hit discovery,” said Christopher Conway, senior vice president, Discovery and Development Services, at AMRI. “Accelerating all phases of drug discovery is critical to our customers. We will be better able to develop protocols using AMRI’s novel, label-free screening assays and extend the utility of the MALDI PharmaPulse technology to complex cell-based assays for the identification of potential new drugs to meet a variety of unmet needs.”


With technical support from these partners, AMRI will apply advanced laboratory automation and MS technologies to provide next generation, high throughput, label-free screening by MS (PharmaPulse). These improved assays and screening strategies will accelerate and enable development of drugs to treat complex diseases that are poorly served by current therapies. AMRI will apply its biological understanding and expertise to extend the utility of MALDI PharmaPulse technology to encompass complex cell-based assays and an expanded portfolio of MS-based biochemical assays.


“The protocols we can develop by applying the latest MS technologies to assay development have enormous potential for many disease areas, including such challenging areas as Alzheimer’s disease and other neurological diseases,” said Grant Carr, Ph.D., senior director, lead discovery, at AMRI. “The extreme sensitivity of Bruker’s MALDI-TOF technology enables us to execute thousands of assays an hour while providing a level of information that often exceeds traditional screening assays.

When coupled with the HighRes’ automation and process integration capabilities embodied in the MALDI PharmaPulse platform, we anticipate that this technique will enable entirely new avenues of drug discovery research.”


“The MALDI PharmaPulse (MPP) solution is a game-changer for high throughput drug screening,” said Paul Speir, senior vice president at Bruker Daltonics. “Combining true label-free detection with ultra-high speed MS analysis, MPP is designed to accelerate drug discovery and development. We are excited to be working with AMRI in the development of new reference assay protocols that pharma customers can customize and use.”


Pharmaceutical companies require high throughput assay technologies to identify “Hits”, the drug development starting points, from large collections of compounds. MALDI PharmaPulse systems combine Bruker’s MALDI-TOF mass spectrometers with high throughput robotics and software from HighRes Biosolutions. The combination provides the first MS-based screening system able to screen > 10,000 test samples per day in Hit discovery mode and complete Hit discovery in a timely, cost effective manner using MS technology. AMRI has targeted a throughput of 100,000 test samples per day to match the requirements of clients refusing to compromise on screen quality.


About AMRI

Albany Molecular Research Inc is a global contract research and manufacturing organization that has been working with the life sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, key business segments include Discovery and Development Services, Active Pharmaceutical Ingredients, Drug Product, and Fine Chemicals. For more information, please visit www.amriglobal.com

 

Tags: America
Previous Post

Allergan Launches See America , a Bold Initiative Furthering the Fight Against Preventable Blindness

Next Post

EC approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis

Related Posts

Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Cellbox Solutions Establishes Subsidiary in the USA
Americas

Cellbox Solutions Establishes Subsidiary in the USA

24th September 2021
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
Americas

US Allows Johnson & Johnson Covid Vaccination To Resume

26th April 2021
POINT Biopharma to Launch First US Manufacturing Facility in Indiana
Americas

POINT Biopharma to Launch First US Manufacturing Facility in Indiana

5th June 2020
AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand
Americas

AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand

5th May 2020
Lilly to invest $400m to boost manufacturing capacity in US
Americas

Lilly to invest $400m to boost manufacturing capacity in US

26th November 2019
Next Post

EC approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In